Results show that higher expression levels for both HMOX1 and ANXA2 are associated with better RFS in PCa patients (HR: 0.5, p = 0.021 for HMOX1; HR: 0.4, p = 0.001 for ANXA2) (Figure 6A, left and right panel, respectively). Here, HMOX1 is linked to posterior cortical atrophy.